Aggressive variants of follicular cell-derived thyroid carcinoma: an overview

Endocrine. 2022 Oct;78(1):1-12. doi: 10.1007/s12020-022-03146-0. Epub 2022 Jul 21.

Abstract

Purpose: The incidence of thyroid carcinoma has increased globally in the past years. Papillary thyroid carcinoma (PTC) is the most frequent neoplasm of the thyroid gland comprehending the 90% of the thyroid carcinoma and has an indolent clinical behaviour. However, some variants of follicular cell-derived thyroid carcinoma, including variants of classic of PTC, have been identified that show a more aggressive biological behaviour. An accurate diagnosis of these entities is crucial for planning a more aggressive treatment and improving patients' prognosis of patients. The aim of this review is to present the main clinical, histological, and molecular features of aggressive variants of follicular cell-derived thyroid carcinoma, and to provide useful histological parameters for determining the most suitable therapeutic strategy for patients affected by these forms.

Results: Variants of classic PTC such as the diffuse sclerosing variant (DSV), the tall cell variant (TCV), the columnar cell variant (CCV), the solid/trabecular variant (STV) and the hobnail variant (HV), and other variants of follicular cell-derived thyroid carcinoma, such as poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC), are associated with aggressive behaviour.

Conclusions: The correct identification and diagnosis of aggressive variants of follicular cell-derived thyroid carcinoma is important, as they allow the clinician to adopt the most refined therapeutic strategies in order to the survival of the patients.

Keywords: Aggressive variants; Anaplastic carcinoma; Papillary thyroid carcinoma; Poorly differentiated carcinoma.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma, Follicular* / pathology
  • Carcinoma, Papillary* / pathology
  • Humans
  • Thyroid Cancer, Papillary
  • Thyroid Neoplasms* / pathology